Immune responses and immunotherapeutic approaches in the treatment against cancer.

Clin Exp Metastasis · 2024 · PMC11374840 · PMID 39155358

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

showed a trendp = 0.053so close (0.05 < p ≤ 0.1)

The combination therapy showed a trend towards longer time without cancer recurrence compared to monotherapy (with a hazard ratio for recurrence or death being 0.561 [95% CI 0.309–1.017]; p = 0.053), and fewer patients experienced cancer recurrence or death (22% in the combination group vs. 40% in the monotherapy group).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.